8T7A

Cryo-EM structure of RSV preF in complex with Fab 2.4K

8T7A の概要

• エントリーDOI: 10.2210/pdb8t7a/pdb
• EMDBエントリー: 41089
• 分子名称: Fusion glycoprotein F2, Fusion glycoprotein F1, 2.4K Fab Heavy Chain, ... (5 entities in total)
• 機能のキーワード: complex, antibody, fusion protein, viral protein, viral protein-immune system complex, viral protein/immune system
• 由来する生物種: Respiratory syncytial virus; 詳細
• タンパク質・核酸の鎖数: 12
• 化学式量合計: 252473.78

構造登録者

McCool, R.S.,McLellan, J.S. (登録日: 2023-06-20, 公開日: 2023-09-13, 最終更新日: 2024-10-23)

主引用文献

McCool, R.S.,Musayev, M.,Bush, S.M.,Derrien-Colemyn, A.,Acreman, C.M.,Wrapp, D.,Ruckwardt, T.J.,Graham, B.S.,Mascola, J.R.,McLellan, J.S.
Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein elicits antibodies targeting a membrane-proximal epitope.
J.Virol., 97:e0092923-e0092923, 2023

PubMed Abstract: Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and pneumonia in infants, infecting all children by age 5. RSV also causes substantial morbidity and mortality in older adults, and a vaccine for older adults based on a prefusion-stabilized form of the viral F glycoprotein was recently approved by the FDA. Here, we investigate a set of antibodies that belong to the same public clonotype and were isolated from individuals vaccinated with a prefusion-stabilized RSV F protein. Our results reveal that these antibodies are highly potent and recognize a previously uncharacterized antigenic site on the prefusion F protein. Vaccination with prefusion RSV F proteins appears to boost the elicitation of these neutralizing antibodies, which are not commonly elicited by natural infection.

PubMed: 37737588
DOI: 10.1128/jvi.00929-23

実験手法

ELECTRON MICROSCOPY (2.8 Å)